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Summary
Apert syndrome, one of five craniosynostosis syndromes
caused by allelic mutations of fibroblast growth-factor
receptor 2 (FGFR2), is characterized by symmetrical
bony syndactyly of the hands and feet. We have analyzed
260 unrelated patients, all but 2 of whom have missense
mutations in exon 7, which affect a dipeptide in the
linker region between the second and third immuno-
globulin-like domains. Hence, the molecular mechanism
of Apert syndrome is exquisitely specific. FGFR2 mu-
tations in the remaining two patients are distinct in po-
sition and nature. Surprisingly, each patient harbors an
Alu-element insertion of ∼360 bp, in one case just up-
stream of exon 9 and in the other case within exon 9
itself. The insertions are likely to be pathological, be-
cause they have arisen de novo; in both cases this oc-
curred on the paternal chromosome. FGFR2 is present
in alternatively spliced isoforms characterized by either
the IIIb (exon 8) or IIIc (exon 9) domains (keratinocyte
growth-factor receptor [KGFR] and bacterially ex-
pressed kinase, respectively), which are differentially ex-
pressed in mouse limbs on embryonic day 13. Splicing
of exon 9 was examined in RNA extracted from fibro-
blasts and keratinocytes from one patient with an Alu
insertion and two patients with Pfeiffer syndrome who
had nucleotide substitutions of the exon 9 acceptor splice
site. Ectopic expression of KGFR in the fibroblast lines
correlated with the severity of limb abnormalities. This
provides the first genetic evidence that signaling through
KGFR causes syndactyly in Apert syndrome.
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Introduction
Apert syndrome (MIM 101200) is a severe autosomal
dominant disorder characterized by craniosynostosis
(premature fusion of the cranial sutures) and bilateral
bony syndactyly of the hands and feet. A variety of other
malformations occur at a lower frequency, including ab-
normalities of the skin, skeleton, brain, and other in-
ternal organs (Upton and Zuker 1991; Park et al. 1995;
Slaney et al. 1996). It is one of five craniosynos-
tosis syndromes associated with allelic mutations of the
fibroblast growth-factor receptor (FGFR) 2 gene
(FGFR2), along with Crouzon, Pfeiffer, Jackson-Weiss
and Beare-Stevenson syndromes (reviewed in Wilkie
1997). Crouzon syndrome is characterized by apparently
normal limbs, whereas in Pfeiffer syndrome (MIM
101600) the thumbs and halluces are broad and there
is sometimes cutaneous syndactyly; the limb phenotype
of Jackson-Weiss syndrome is variable and usually in-
termediate in severity (Gorlin et al. 1990); Beare-Ste-
venson syndrome is associated with the cutaneous dis-
orders cutis gyrata and acanthosis nigricans (Przylepa et
al. 1996).
FGFRs are transmembrane receptor tyrosine kinase
proteins involved in signaling pathways via interaction
with fibroblast growth factors (FGFs), 18 of which have
been characterized to date (Hu et al. 1998; Ohbayashi
et al. 1998). The receptors consist of three extracellular
immunoglobulin-like domains (IgI, IgII, and IgIII), a
transmembrane domain, and an intracellular split ty-
rosine kinase domain. After ligand binding, the receptors
dimerize and signaling is activated by autophosphory-
lation of intracellular tyrosine residues (Spivak-Kroiz-
man et al. 1994). The complexity of FGFR2 is increased
by mutually exclusive alternative splicing of exons 8 and
9, leading to two forms of the receptor, keratinocyte
growth-factor receptor (KGFR) and bacterially ex-
pressed kinase (BEK), which differ in the C-terminal half
of the IgIII domain (exon numbering herein is based on
the mouse Fgfr2 described by Twigg et al. [1998]).
KGFR is characterized by splicing of the IIIa (exon 7)
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Figure 1 Structure of FGFR2, showing positions of mutations, polymorphic nucleotides, and primers used in the present study. The outline
of FGFR2 protein (top) shows the leader sequence (L), acid box (A), three immunoglobulin-like domains (IgI, IgII, and IgIII), a transmembrane
domain (TM), and a split tyrosine-kinase domain (TK1 and TK2). Alternative splicing of the second half of the IgIII domain is shown by IgIIIb
(KGFR isoform) and IgIIIc (BEK isoform), encoded by exons and 8 and 9 respectively. Selected previously described mutations and the positions
of the Alu insertions in patients 1 and 2 (with Apert syndrome), as well as the nucleotide substitution in patients 3 and 4 (with Pfeiffer syndrome),
are shown diagrammatically on the partial genomic structure, along with the positions of primers (not to scale).
domain to the IIIb (exon 8) domain, whereas BEK is
characterized by splicing of the IIIa domain to the IIIc
(exon 9) domain (fig. 1). KGFR is expressed primarily
in epithelial cell types, whereas BEK is expressed in other
cell types, and the two isoforms have different ligand
specificities: FGF7 and FGF10 bind specifically to
KGFR, whereas BEK exhibits a broader ligand specificity
(Dell and Williams 1992; Miki et al. 1992; Gilbert et
al. 1993; Ornitz et al. 1996; Del Gatto et al. 1997; Car-
stens et al. 1998; Xu et al. 1998).
All FGFR2 mutations identified to date are domi-
nantly inherited, and the observation that different cran-
iosynostosis syndromes result from allelic missense mu-
tations of the same gene implies that the mutations act
by a variety of gain-of-function mechanisms. Within
FGFR2, three main classes of mutation have been iden-
tified. Most patients in the Crouzon/Pfeiffer/Jackson-
Weiss group have mutations clustered in the body of the
third immunoglobulin-like domain, either in exon 7
(IIIa) or in exon 9 (IIIc) (fig. 1). The similar phenotype
arising from mutation of these two exons argues that
craniosynostosis is caused by abnormality of the BEK
isoform, because the KGFR isoform is not affected by
the exon 9 mutations. The mutations frequently involve
gain or loss of cysteine or substitution of conserved bur-
ied residues, suggesting that they lead, directly or indi-
rectly, to covalent dimerization of FGFR2 molecules and
constitutive activation of signaling. Recent functional
studies for certain mutations support the involvement of
these mechanisms (Neilson and Friesel 1996; Robertson
et al. 1998). The Beare-Stevenson mutations, substitu-
tions to cysteine in the extracellular juxtamembrane re-
gion, constitute a distinct class but probably act by a
similar mechanism.
The third class of mutations are those causing Apert
syndrome, which show different properties and probably
act by a distinct mechanism. They occur within the pu-
tative linker region between the IgII and IgIII domains,
which is located in a sequence of 16 amino acids con-
served between all four human FGFRs (Johnson and
Williams 1993). Mutations of this region in FGFRl,
FGFR2, and FGFR3 give rise to distinct syndromes. In
FGFR2, we have identified, in 258/260 unrelated cases
of Apert syndrome, mutations that involve amino acid
substitutions of a serine-proline dipeptide in exon 7 (172
Ser252Trp, 1 Ser252Phe, and 85 Pro253Arg) (Park et
al. 1995; Wilkie et al. 1995; Oldridge et al. 1997; and
combined data of Oxford and Johns Hopkins groups
[authors’ unpublished data]). Equivalent ProrArg mu-
tations in FGFR1 (Pro252Arg) and FGFR3 (Pro250Arg)
cause Pfeiffer and Muenke syndromes, respectively
(Muenke et al. 1994; Bellus et al. 1996). None of these
mutations involves gain or loss of cysteine residues, but
all are substitutions to bulky side-chain amino acids.
Both the IgII and IgIII domains are involved in the bind-
ing of FGF ligand, suggesting that these mutations lead
to changes in the relative orientation of the two domains
and hence could accentuate ligand binding. Supporting
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this is the recent demonstration that the Apert mutations
cause reduced dissociation of FGF2 ligand from the BEK
isoform of FGFR2, the effect being more marked for
Ser252Trp than for Pro253Arg (Anderson et al. 1998a).
Although these recent findings provide insight into the
molecular mechanism of the morphological abnormal-
ities of Apert syndrome, they do not explain two other
clinical observations. First, the two common mutations
are associated with differential effects on cleft palate and
syndactyly: cleft palate is more frequent with the
Ser252Trp mutation, whereas syndactyly is more severe
with the Pro253Arg mutation (Slaney et al. 1996). The
latter trend runs counter to the prediction, from in vitro
studies of BEK, that the Ser252Trp mutation should ex-
hibit a greater biological effect (Anderson et al. 1998a).
In one patient with a Ser252Trp mutation, the syndac-
tyly was so mild that the phenotype suggested Pfeiffer
syndrome rather than Apert syndrome (Passos-Bueno et
al. 1998). Second, given the specificity of the Apert mu-
tations, the report of a patient with a phenotype similar
to Apert syndrome (craniosynostosis, 3-4 syndactyly of
the hands, and complete syndactyly of the feet) but with
a different molecular pathology was surprising (Passos-
Bueno et al. 1997). This patient had a nucleotide sub-
stitution of the 3′ splice site upstream of exon 9, 1119-
2ArG (cDNA numbering is from Dionne et al. 1990),
a mutation elsewhere described in four cases of Pfeiffer
syndrome (fig. 1) (Lajeunie et al. 1995; Schell et al. 1995;
Passos-Bueno et al. 1997). These observations indicate
that the mechanism of the syndactyly in Apert syndrome
remains to be elucidated.
Here we describe the mutations identified in the 2
individuals, from our series of 260 patients with Apert
syndrome, who did not have mutations of the exon 7
serine-proline dipeptide. Surprisingly, different de novo
Alu-element insertions are present in both individuals:
in one case the insertion lies just upstream of exon 9,
and in the other case it is within the exon itself. Given
the likely effects of these mutations on alternative splic-
ing, we obtained fibroblast and keratinocyte cell lines
from one of these patients, as well as from two patients
with Pfeiffer syndrome who have point mutations at the
position identical to that reported for the patient with
atypical Apert syndrome reported by Passos-Bueno et al.
(1997). The finding of ectopic KGFR expression in fi-
broblasts from these patients defines a new pathological
class of FGFR2 mutations and leads us to formulate a
hypothesis for the mechanism of syndactyly in Apert
syndrome. This correlates with the expression pattern
of the Fgfr isoforms in early mouse limb buds.
Subjects and Methods
Patients
Patient 1 is shown in figure 2A. She was born at 38
wk gestation, weighing 3.26 kg. At the time of her birth,
her mother was age 35.1 years and was noted to have
mild exorbitism; the father was age 35.4 years and was
clinically normal. The patient had cranial features of
Apert syndrome, with brachycephaly, hypertelorism, oc-
ular proptosis, and midface hypoplasia. In addition, the
palate was high arched but not cleft. Skull x-rays con-
firmed bicoronal synostosis. The hands and feet showed
complete syndactyly of digits 1–5, corresponding to
morphological scores of 3 (themost severe grade) (Upton
1991). On plain radiography (fig. 2A), the hands showed
partial transverse fusion of the 4th and 5th metacarpals
and longitudinal fusion of the proximal and middle pha-
langes of digits 3 and 4, and the thumbs had a single
phalanx. The feet showed partial transverse fusion of
the 1st and 2d metatarsals on the left and longitudinal
fusion of the proximal and middle phalanges of dig-
its 2–5. The halluces had a single large delta-shaped
phalanx.
An unusual finding for Apert syndrome was scoliosis,
noted at age 3 years. Radiographs of the spine showed
multiple fusions of thoracic vertebrae T4–T9, with
anomalous vertebral bodies and secondary rib fusions.
Developmental progress was good, and the patient was
attending a normal school at age 7 years. Surgery had
been performed for her craniosynostosis, syndactyly, and
scoliosis.
Patient 2 is shown in figure 2B.He had typical clinical
features of Apert syndrome, as described elsewhere (case
FA-17 reported by Park et al. [1995]). In brief, this male
patient was born at 40 wk gestation, weighing 4.11 kg.
The parents were clinically normal; at the time of the
patient’s birth, the mother was age 32.1 years, and the
father was age 32.6 years. The patient’s craniofacial
anomalies included turribrachycephaly with craniosy-
nostosis, hypertelorism, ocular proptosis, mild malar hy-
poplasia, choanal atresia, and a high, narrow, but non-
cleft palate. Scoliosis was diagnosed at age 1.5 years but
has remained stable with physical therapy. On recent
assessment at age 8.7 years, the patient’s height was 123
cm (10th centile), and he had required surgery for cran-
iosynostosis, syndactyly, and choanal atresia. There was
complete syndactyly of the hands and feet (type 3). Se-
vere developmental delay was apparent: he had no
speech, communicated with simple signs, walked with a
broad-based gait, and had poor fine-motor skills. Ad-
ditional features were strabismus with amblyopia and
bilateral contractures of the elbows with rhizomelia.
Patients 3 and 4 had Pfeiffer syndrome. Craniofacial
features included exorbitism, ocular hypertelorism, and
midface hypoplasia, and skull radiographs demonstrated
craniosynostosis in both cases (not illustrated). These
patients had limb phenotypes at the severe end of the
spectrum for Pfeiffer syndrome, with very broad, radi-
ally deviated thumbs and halluces. In addition, patient
3 had 2-3 cutaneous syndactyly of the feet, and patient
Figure 2 Phenotype of patients with Apert syndrome caused by Alu-element insertions. A, Patient 1, showing facial features post cra-
niectomy and cranial remodeling (top), preoperative appearance of hands and feet (middle), and radiographs of right hand and left foot at age
5 mo (bottom). B, Patient 2, showing appearance of skull and limbs (top) and close-up of right foot (bottom).
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Figure 3 Appearance of limbs in patients with Pfeiffer syndrome who were investigated in the present study. A, Hands and feet of patient
3. B, Left hand and foot of patient 4.
4 had partial 1-2 cutaneous syndactyly of the feet (fig.
3). Radiographs of the hands and feet of patient 3
showed short, malformed 1st metacarpals and metatar-
sals. Mutations of FGFR2 were identified in these pa-
tients by abnormal migration of exon 9 PCR products
on single-strand conformational polymorphism gels, fol-
lowed by direct sequencing (not illustrated). Patient 3
had a 1119-2ArG substitution of the 3′ splice site up-
stream of exon 9. This is a relatively common FGFR2
mutation in Pfeiffer syndrome (Lajeunie et al. 1995;
Schell et al. 1995; Passos-Bueno et al. 1997) and is iden-
tical to the mutation in the patient with atypical Apert
syndrome described by Passos-Bueno et al. (1997). Pa-
tient 4 had a different substitution of the same nucleo-
tide, 1119-2ArT, elsewhere described in a single patient
with Pfeiffer syndrome (Anderson et al. 1998b).
For all sampling procedures, informed consent was
given by the patients. Genomic DNA was prepared from
peripheral blood samples. Skin biopsies were obtained,
under general anesthetic, from patients 1, 3, and 4 dur-
ing planned operative procedures and were used to ob-
tain cultures of keratinocyte and fibroblast cells.
PCR Amplification
Oligonucleotides specific for FGFR2 are listed in table
1, and their positions are indicated in figure 1. Ge´ne´thon
markers were purchased from Research Genetics. PCR
was performed in a total volume of 25 ml containing 40
ng of DNA, 120 mM each dNTP, 10 mM Tris pH 9, 50
mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100, 0.01%
gelatin, 0.4 mM primers, and 0.4 U of AmpliTaq DNA
polymerase (Perkin-Elmer). Thermocycling was per-
formed on a Hybaid Omnigene Temperature Cycler and,
unless otherwise stated, consisted of one cycle of 4 min
at 94C, 1 min at 62C, and 30 s at 72C, followed by
33 cycles of 1 min at 94C, 1 min at 62C, and 30 s at
Oldridge et al.: Alu Insertion of FGFR2 in Apert Syndrome 451
Table 1
Sequence and Purpose of Oligonucleotides
Oligonucleotide
Sequencea
(5′r3′) Purpose
6/7BF TGGCATGAGGTCACTGACAG Exon 7 sequencing
5/6R2 CCAACAGGAAATCAAAGAACC Exon 7 sequencing
R2I9F AATCATTCCTGTGTCGTCTAACC PCR across exon 9
R2I9R AAAAACCCAGAGAGAAAGAACAG PCR across exon 9
7/8GF AAAACCCTGACCTTTGAAATCC PCR of intron 7 polymorphism
7/8GR CGTGGTAGGCAAGGAGTTAAGAG PCR of intron 7 polymorphism
9/10PolyF TGCTTTCATCCCACTTTG PCR of intron 9 polymorphism
9/10PolyR AGCAAACCACAGTCTCTG PCR of intron 9 polymorphism
7/8FF ATACTCTGTCCCCCATAGGGCGG PCR of intron 7/Alu (patient 1)
7R CAATCTCTTTGTCCGTGGTG PCR of intron 7/Alu (patient 1)
DPOLC GTCATATTTCTGCACCAGTG Intron 7 ASO (C allele)
DPOLA CACTGGTGCATAAATATGAC Intron 7 ASO (A allele)
9/10PolyC TAGAATGGACTTTCGGTT Intron 9 ASO (C allele)
9/10PolyT AACCAAAAGTCCATTCTA Intron 9 ASO (T allele)
4F GGGTCCATCAATCACACGTAC RT-PCR
9R GGCGTGTTGTTATCCTCACCAG RT-PCR
SPL7/8 GTTCTCAAGCACTCGGGGA Exon 7/8 junction oligonucleotide
SPL7/9 GTTCTCAAGGCCGCCGGT Exon 7/9 junction oligonucleotide
SPL7/10 GTTCTCAAGCGCCTGGAAG exon 7/10 junction oligonucleotide
SPL7/11 GTTCTCAAGGTTTCGGCTGA Exon 7/11 junction oligonucleotide
a Polymorphic bases are underlined.
72C and a final step of 1 min at 94C, 1 min at 62C,
and 10 min at 72C.
FGFR2 Mutation Analysis
DNA was prepared from leukocytes by proteinase K
digestion and phenol/chloroform extraction. DNA was
amplified by PCR using primers 6/7BF-5/6R2 (exon 7)
and R2I9F-R2I9R (exon 9). The samples were run on
2% agarose gels, the bands were excised, and DNA was
extracted by the Qiaquick gel-purification kit (Qiagen).
The DNA was then sequenced with the primers cited
above, by the Thermo Sequenase cycle-sequencing kit
(Amersham).
Determination of Parental Origin of Alu Insertions
The patients and family members were genotyped for
two polymorphisms within FGFR2: a C/A variant in
intron 7 (Moloney et al. 1996) and a C/T variant in
intron 9 (W. Jiang, unpublished data). Genotypes at the
C/A variant were determined by BsgI digestion of the 7/
8GF-7/8GR PCR product (Moloney et al. 1996). Geno-
types at the C/T variant were determined by elec-
trophoresis of duplicate 9/10PolyF-9/10PolyR PCR
products on 2% agarose gels, blotting onto Zeta probe
membrane (Bio-Rad), and hybridization with allele-spe-
cific oligonucleotides (ASOs) for the T and C alleles—9/
10PolyT and 9/10PolyC, respectively. The hybridization
was performed at 42C in 7% polyethylene glycol/10%
SDS, and washing performed at 65C in /0.1%2# SSC
SDS for 10 min. Correct paternity of offspring was con-
firmed by use of the polymorphic CA-repeat markers
D1S207, D2S102, D6S470, D16S407, and D20S27
(Dib et al. 1996).
DNA was amplified by PCR using primers flanking
both an informative polymorphism and the site of Alu
insertion, by the Expand kit (Boehringer Mannheim). In
patient 1, the C/A variant was amplified with the primer
pair 7/8FF-7R, with an extension time of 3 min. In pa-
tient 2, the C/T variant was amplified with primer pair
R2I9F-9/10PolyR, with an extension time of 2 min. The
products were run in duplicate on 1% agarose gels and
hybridized with oligonucleotides designed to bind to one
or the other of the polymorphic alleles. Hybridization
and washing were performed as described above.
RNA Analysis
RNA was prepared from fibroblast and keratinocyte
cell lines derived from skin samples (Chomczynski and
Sacchi 1987). Reverse transcriptase–PCR (RT-PCR) was
performed with 10 mg of RNA in first-strand synthesis
in a total of 40 ml containing 340 pmol of random hex-
amer primers, 32 U of RNase inhibitor (Boehringer
Mannheim), and 400 U of Moloney murine leukemia
virus reverse transcriptase (Gibco BRL). Four microliters
of cDNA was then used in a PCR reaction containing
40 mM dNTP with the primer pair 4F-9R, to amplify
the segment of the FGFR2 message starting in exon 6
and finishing in exon 11 (1-min extension time). The
products were run on a 2% agarose gel, blotted, and
hybridized to oligonucleotides designed to bind specifi-
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cally to various splice variants (table 1). The conditions
for hybridization were as described above. To measure
the BEK:KGFR ratio, 50 pmol of primer 4F was 5′ end-
labeled with T4 polynucleotide kinase (New England
Biolabs) in a volume of 25 ml and was purified by being
passed through a Sephadex G25 column. One microliter
of labeled primer was used with 0.4 mM unlabeled 4F
and 9R and 4 ml of cDNA, in a PCR reaction with 28
amplification cycles (pilot experiments established that
this was prior to the plateau phase). The products were
digested with either HpaI (which cleaves BEK but not
KGFR) or AvaI (which cleaves KGFR but not BEK),
and the samples were run on a nondenaturing poly-
acrylamide gel (8% acrylamide [w/v], 0.27% bisacryla-
mide, ) at 35 V for 6 h. The gel1# Tris-borate EDTA
was exposed to a Storage Phosphor Screen (Kodak) over-
night, and the radioactivity was quantified on a Storm
850 PhosphorImager (Molecular Dynamics). The rela-
tive intensities of the digested and undigested products
were analyzed by Storm Imagequant software.
In Situ Hybridization of Embryonic Mouse Limbs
In situ hybridization was performed on paraformal-
dehyde-fixed whole limbs frommouse embryos obtained
13 d after mating (E13), with digoxygenin-labeled ri-
boprobes specific for the mouse Fgfr2 splice variantsBek
and Kgfr. For the Bek-specific probe, a 162-bp PpuMI-
HaeII fragment from the mouse Bek cDNA IgIIIc region
was used as template. For the Kgfr-specific probe, a 122-
bp PpuMI-EcoRV fragment from the mouse Kgfr cDNA
IgIIIb region was used. Antisense and sense transcripts
were generated as described elsewhere (Iseki et al. 1997).
The specimens were subsequently embedded in gloop (a
mixture of glutaraldehyde and albumen), for vibratome
sectioning at 50 mm, to detect tissue-specific localization
of RNA transcripts.
Results
Identification of Alu-Element Insertions in Patients 1
and 2
The DNA sequence of exon 7 was normal. We ana-
lyzed exon 9 for mutations, by amplification with oli-
gonucleotides R2I9F and R2I9R, which correspond to
sequences in the flanking introns. Surprisingly, fragments
of ∼590 bp and ∼575 bp were generated from the DNA
of patients 1 and 2, respectively, in addition to the ex-
pected product of 225 bp; the larger fragments were not
present in unaffected relatives (fig. 4A and B). The larger
PCR fragments were excised, gel purified, and se-
quenced. Both were found to contain Alu-element in-
sertions. Patient 1 has an insertion of 368 bp within
intron 8, 1119-3–-4insAlu. The Alu element is inserted
in the orientation opposite to that of FGFR2 and con-
tains a run of 69 A residues at its 3′ end and a repeat
flanking sequence of 16 bp (fig. 4C). Patient 2 has an
insertion of ∼350 bp (the exact number of A residues
was not determined) within exon 9, 1220–1221 insAlu.
This Alu element is also inserted in the opposite orien-
tation and contains a run of 44–50 A residues with a
repeat flanking sequence of 15 bp (fig. 4D). The sequence
of the flanking direct repeats does not match the pro-
posed consensus very closely, although the pentanucleo-
tide 5′ TAGAA-3′ (relative to the Alu sense strand) is
shared by both insertions at one of the proposed sites
of nicking (Jurka 1997). In figure 5, the sequence of the
two Alu elements inserted is compared with that of Alu
Y–family members described elsewhere (Batzer et al.
1996) and with previously identified disease-causingAlu
elements (table 2). The Alu element in patient 1 is most
closely related to the AluYa5 family, whereas the Alu
element in patient 2 is most closely related to theAluYb8
family.
Both Alu insertions arose de novo in the patients. In
family 1 this was demonstrated directly (fig. 4A),
whereas in family 2, in the absence of a DNA sample
from the deceased father, this could be deduced because
sibling A21 inherited the same FGFR2 haplotype from
the father (not illustrated) but did not show the insertion
(fig. 4B).
Parental Origin of Alu Insertions
Family 1 was informative for a C/A polymorphism in
intron 7 (patient 1, CA; mother, CC; father, AA). The
DNA segment containing both the polymorphism and
the Alu insertion was amplified with primers 7/8FF and
7R: in addition to the normal ∼2.25-kb band, the patient
showed a ∼2.60-kb band containing theAlu element (fig.
6A). Duplicate gels were blotted and hybridized to
ASOs. Oligonucleotide DPOLC hybridized to the ma-
ternal fragment and to the patient’s normal-sized frag-
ment, whereas oligonucleotide DPOLA hybridized to the
paternal fragment and to the patient’s larger Alu-con-
taining fragment, demonstrating the paternal origin of
the Alu (fig. 6A).
Patient 2 was homozygous for the intron 7 polymor-
phism but heterozygous for the C/T polymorphism in
intron 9. Although the mother was also heterozygous
for the intron 9 polymorphism, by creating haplotypes
we deduced that patient 2 had received the T allele from
his mother and had received the C allele from his father
(not illustrated). Amplification with primers R2I9F and
9/10PolyR yielded a product containing the informative
polymorphism and theAlu insertion. Duplicate gelswere
blotted and hybridized to ASOs. 9/10PolyT hybridized
to the normal allele of the patient, and 9/10PolyC hy-
bridized to the allele containing the Alu insertion (fig.
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Figure 4 Amplification of FGFR2 exon 9 and flanking intron sequence. A and B, PCR products from patients 1 (A) and 2 (B) and their
available family members, with primers R2I9F and R2I9R. All samples contained the expected 225-bp product, but patients 1 and 2 also
showed DNA fragments of ∼590 bp and ∼575 bp, respectively, containing the inserted Alu elements. C, Position and orientation of Alu element
inserted into intron 8 of patient 1. D, Position and orientation of Alu element inserted into exon 9 of patient 2. The repeat flanking sequence
is underlined, the exon sequence is boldface, and cDNA is based on the numbering used by Dionne et al. (1990).
6B). This showed that the Alu insertion is in cis to the
C allele and therefore is also paternally derived.
We conclude that both mutations probably arose in
the father’s germ line, in keeping with the exclusively
paternal origin of newmutations in Apert syndrome that
has been described elsewhere (Moloney et al. 1996). In-
tegration into the paternally derived chromosomeduring
early embryogenesis is a possibility, although there was
no evidence of mosaicism in either patient.
Analysis of FGFR2 Splicing
The position of the Alu element in patient 1, just up-
stream of the start of exon 9, suggested that it might
affect utilization of the 3′ splice site, leading to the gen-
eration of different splice forms. Mutations of this ac-
ceptor site have been recorded in several cases of Pfeiffer
syndrome and in one patient with an Apert-like phe-
notype (see Introduction), although the consequences for
splicing have not previously been investigated. We con-
sidered it important to document the effect of splicing
in these cases and studied two patients with Pfeiffer syn-
drome: patient 3, with a 1119-2ArG mutation, and pa-
tient 4, with a 1119-2ArT mutation (these mutations
are henceforth referred to as “-2ArG” and “-2ArT,”
respectively). Of note is that both these patients had very
marked radial deviation and broadening of the 1st digits
of both the hands and feet, with some soft-tissue syn-
dactyly (fig. 3A and B).
We prepared cDNA from fibroblasts and keratino-
cytes derived from representative controls, patients with
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Figure 5 Sequence of Alu elements inserted into patients 1 and 2, compared with Alu Y family members (Batzer et al. 1996) and previously
described pathological Alu insertions (table 2). Alu Y  major Alu subfamily; BRCA2  breast cancer gene; Alu Ya5  Alu Y subfamily
member; CASR  calcium-sensing receptor gene; NF1  neurofibromin gene; F9  factor IX gene; Alu Yb8  Alu Y subfamily member;
BCHE  cholinesterase gene.
the canonical Apert syndrome mutations, patient 1 (with
the Alu insertion), and patients 3 and 4 (with Pfeiffer
syndrome) (these cell lines were not available from pa-
tient 2). RT-PCR was performed with primers located
within exons 6 (4F) and 11 (9R), encompassing the en-
tire IgIII and transmembrane domains, to avoid biased
amplification of particular alternatively spliced products
(fig. 1). A single major RT-PCR product of ∼640 bp was
obtained from all samples, which corresponds in size to
the full-length KGFR (exons 6-7-8-10-11) or BEK (exons
6-7-9-10-11) isoforms. In addition, a number of faint
lower-molecular-weight bands were visible in some lanes
(fig. 7, top panel).
To identify the splice forms corresponding to the PCR
products, we blotted the gel and hybridized the products
with oligonucleotides specific to various exon junction
fragments. The results of hybridization to SPL7/9 (spe-
cific for the BEK isoform) and SPL7/8 (specific for the
KGFR isoform) are shown in figure 7. Whereas, as ex-
pected, fibroblast lines from a normal individual and
patients with canonical Apert mutations expressed only
BEK, the fibroblasts from patients 1, 3, and 4 demon-
strated ectopic KGFR expression (fig. 7,middle and bot-
tom panels). All the keratinocyte cell lines showed only
KGFR expression. Additional, fainter RT-PCR products
in figure 7, most apparent in the fibroblast lines of pa-
tients 1, 3, and 4, were identified as 6-7-10-11 and 6-
7-11 splice forms, by oligonucleotides SPL7/10 and
SPL7/11, respectively. We conclude that mutations of the
3′ splice site of exon 9 indeed disrupt normal utilization
of this exon in fibroblasts. The ectopic expression of
KGFR is particularly interesting, because this would ex-
tend the ligand sensitivity of the cell to include FGF7
and FGF10.
To determine whether the limb-phenotype differences
between patients 1, 3, and 4 correlated with the level of
ectopic KGFR expression, we performed preliminary
quantitation experiments by measuring the relative
amounts of the two isoforms after restriction-enzyme
cleavage (see Subjects and Methods). Patient 1, with the
Alu insertion causing Apert syndrome, showed the high-
est ectopic expression of KGFR, with 23% of the total
expression of KGFR and BEK, followed by patient 3,
with 12%, and patient 4, with 4%. If these values are
normalized to an equal level of BEK expression (which
assumes that all BEK is expressed from the wild-type
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Table 2
Comparison of Pathological Alu Insertions
Gene Disorder
Alu
Family Insertion Orientation
De
Novo? Functional Effect Reference
NF1 Neurofibromatosis Ya5 Intron Antisense Yes Exon skippingr
truncation
Wallace et al. (1991)
BCHE Acholinesterasemia Yb8 Exon Sense No Muratani et al. (1991)
F9 Hemophilia B Ya5 Exon Sense Yes Vidaud et al. (1993)
CASR Familial hypocalciuric
hypercalcemia
Ya5 Exon Antisense No Janicic et al. (1995)
BRCA2 Breast cancer Y Exon Sense Exon skippingr
truncation
Miki et al. (1996)
APC Hereditary desmoid
disease
Exon Sense No Halling et al. (1997)
BTK X-linked
agammaglobulinemia
Y Exon Antisense Yes Lester et al. (1997)
IL2RG X-linked severe combined
immunodeficiency
Ya5 Intron Antisense No Lester et al. (1997)
EYA1 Branchio-oto-renal
syndrome
Ya5 Exon Antisense Yes Abdelhak et al. (1997)
FGFR2 Apert syndrome Ya5 Intron Antisense Yes Ectopic expression of
alternative splice form
Present study
FGFR2 Apert syndrome Yb8 Exon Antisense Yes Present study
allele and that the BEK expression level is equal in the
three patients), the ratio of ectopic KGFR expression in
patients 1, 3, and 4 is approximately 7:3:1.
Expression of Kgfr and Bek Isoforms in Embryonic
Mouse Limbs
In whole E13 mouse limbs, both Kgfr- and Bek-spe-
cific probes hybridized to the interdigital mesenchyme,
with the Bek-specific probe giving a signal much more
intense than that of Kgfr (fig. 8A and B). Bek expression
was also detectable both adjacent to the differentiated
cartilage and at the growing tips of the digits (fig. 8B).
Sections revealed that both Fgfr2 isoforms were ex-
pressed in the surface ectoderm, but Kgfr transcripts
were more abundant than Bek transcripts (fig. 8C and
D). The sections also confirmed that, in the interdigital
mesenchyme, Bek transcripts were more abundant than
Kgfr transcripts; similarly, both probes hybridized to the
mesenchyme surrounding the digital cartilages, but Bek
gave a much stronger signal. Overall, these results in-
dicate that, although both splice variants of Fgfr2 are
expressed in both mesenchymal and epithelial tissues in
the early hand plate, Kgfr expression predominates in
the surface epithelium whereas Bek is predominantly
mesenchymal.
Discussion
We have studied 260 patients with Apert syndrome
and have found that all but 2 have mutations of a Ser-
Pro dipeptide in the linker region between the IgII and
IgIII domains of FGFR2 (exon 7). The 2 patients de-
scribed in the present paper have a phenotype very sim-
ilar to that in the other 258 cases, including craniosy-
nostosis and severe syndactyly of the hands and feet, but
harbor very different mutations; both contain Alu-ele-
ment insertions, the first just upstream of exon 9 and
the second within the middle of exon 9.
The finding of independent, de novo Alu insertions in
FGFR2, separated by only 105 bp, in the two patients
with Apert syndrome who have a normal sequence of
the Ser-Pro dipeptide is strong evidence that these in-
sertions cause the Apert phenotype in these patients. The
observation that a very similar, specific phenotype may
result from two distinct mutational processes affecting
different parts of FGFR2 is remarkable, and no expla-
nation of the phenotypic similarity is immediately ob-
vious. However, this may be viewed as an opportunity
to seek a deeper understanding of the mechanism(s) by
which Apert mutations lead to the characteristic mor-
phological abnormalities. Before considering this, how-
ever, we will first discuss a distinct area of biology il-
456 Am. J. Hum. Genet. 64:446–461, 1999
Figure 6 Paternal origin of Alu insertions. A, Patient 1 and parents, analyzed for intron 7 (C/A) polymorphism. Top, PCR-amplification
products, with primers 7/8FF and 7R. Bottom, Results of hybridization to oligonucleotides DPOLC and DPOLA, specific for the C and A
alleles, respectively. The Alu-containing allele originates from the father. B, Patient 2 and controls, analyzed for intron 9 (C/T) polymorphism.
Top, PCR-amplification products, with primers R2I9F and 9/10PolyR. Bottom, Results of hybridization to oligonucleotides 9/10PolyT and 9/
10PolyC, specific for the T and C alleles, respectively. The Alu-containing allele hybridizes to the C-specific oligonucleotide, indicating that it
is paternally derived.
luminated by this work, the process of Alu-element
retroposition.
Biology of Alu Insertion
The Alu elements are members of the short inter-
spersed nuclear element (SINE) family of repeat elements
and are the most abundant complex repeats found
within the human genome, at a copy number of
1500,000 (reviewed by Schmid 1996). They are evolu-
tionarily derived from the 7SL RNA gene, and their mo-
bilization is thought to arise from transcription by RNA
polymerase III, followed by coupled reverse transcrip-
tion/integration into the genome. The poly-A tract is
indicative of an RNA intermediate, and the flanking re-
peats provide a signature for the mechanism of integra-
tion. Retroposition of Alu elements is believed to require
L1 reverse transcriptase, although the precisemechanism
remains unproved (Boeke 1997).
The major phase of Alu expansion is thought to have
occurred 40 million years ago, and it is estimated that,
at present, de novo Alu-integration events occur rarely,
∼1/100 births (Deininger and Batzer 1995). Relatively
recent Alu integrations may manifest as phenotypically
silent polymorphisms in the human population (Batzer
et al. 1995) or as pathological mutations: table 2 sum-
marizes both the nine pathological Alu insertions that
have been described elsewhere and the two cases pre-
sented here. The Alu sequences can be divided into dif-
ferent subfamilies, according to diagnostic mutations of
the consensus sequence. The Alu insertions in patients
1 and 2 are most closely related to the Ya5 and Yb8
subfamilies, respectively, with the major diagnostic dif-
ference between the two being the insertion of a 7-bp
sequence in the Yb8 subfamily (fig. 5). Both, however,
are distinct from previously described mutations. Both
Ya5 and Yb8 are subsets of the AluY subfamily. This
youngest of the major subfamilies represents only 0.4%
of genomic Alu elements, but all pathological Alu in-
sertions (including those from patients 1 and 2) belong
to this subfamily, indicating that only a small number
of source Alu genes are actively mobile.
Comparison, in table 2, of the pathological Alu in-
sertions described elsewhere and the two FGFR2 inser-
tions described here highlights the following points.
First, all mutations described elsewhere have affected
different genes, whereas we have identified two inde-
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Figure 7 Analysis of FGFR2 expression in fibroblasts and ker-
atinocytes from patients with FGFR2 mutations. Top, PCR-amplifi-
cation products from cDNA, by primers 4F (exon 6) and 9R (exon
11). Lanes 1–6, Products from fibroblast cell lines: lane 1, normal
control; lane 2, Apert (Ser252Trp); lane 3, Apert (Pro253Arg); lane
4, patient 1; lane 5, patient 3; lane 6, patient 4. Lanes 7–10, Products
from keratinocyte cell lines: lane 7, Crouzon (Gly338Arg); lane 8,
Apert (Ser252Trp); lane 9, patient l; lane 10, patient 4. Arrowheads
indicate minor products identified by their size and hybridization to
the specific splice-junction oligonucleotides, SPL7/10 and SPL7/11.
Bottom, Results of hybridization to oligonucleotides SPL7/9 and SPL7/
8, which are specific to the BEK and KGFR isoforms, respectively.
pendent Alu insertions into FGFR2, only 105 bp apart.
Second, all the disorders in which Alu insertions have
elsewhere been described either are recessive or are dom-
inant haploinsufficiencies, indicating loss of function; by
contrast, Apert syndrome is considered to be a domi-
nant, gain-of-function disorder. Third, in the only two
cases analyzed elsewhere at the RNA level (NF1 and
BRCA2), the Alu insertion was shown to cause exon
skipping, setting a precedent for the alteration of FGFR2
splicing that we have observed. Evidence that the Alu
insertions act by a novel gain-of-function mechanism is
discussed below.
Pathogenesis of Syndactyly in Apert Syndrome:
Insights from Alu Insertions
The discovery of Alu insertions within or just up-
stream of the alternatively spliced exon 9 (IIIc) is sur-
prising, because many missense mutations of this exon
have elsewhere been described in craniosynostosis syn-
dromes (Crouzon, Pfeiffer, and Jackson-Weiss syn-
dromes) with normal or mild limb phenotypes (fig. 1).
An explanation of the Apert phenotype of the Alu mu-
tations must account for this discrepancy. Our hypoth-
esis that the insertions might disrupt the normal splicing
of the IIIc exon would also have to explain why pre-
viously described mutations of the 3′ splice site of exon
9 usually had been found to result in a Pfeiffer syndrome
phenotype, although in a single instance an Apert-like
phenotype had been observed (Lajeunie et al. 1995;
Schell et al. 1995; Passos-Bueno et al. 1997). We there-
fore chose to include in our study two patients with
Pfeiffer syndrome who had mutations of this splice site.
Of note is that the limb abnormalities of these patients
(fig. 3) were more severe than those in any of the other
patients with Pfeiffer syndrome in our series, with very
broad, medially deviated first digits of both hands and
feet and with some soft-tissue syndactyly. Corroborating
this, a recent study of the feet of 22 patients with Pfeiffer
syndrome identified the most severe abnormalities in a
patient with the same FGFR2 mutation as was seen in
our patient 4 (Anderson et al. 1998b).
Analysis of FGFR2 expression in keratinocyte and fi-
broblast lines from patient 1, with Apert syndrome and
the Alu insertion, and from the patients with Pfeiffer
syndrome revealed ectopic expression of the KGFR iso-
form within fibroblasts, which was not observed in fi-
broblasts from patients with either of the canonical
Apert mutations. Our findings contrast with the situa-
tion in vitro, in which partial deletion of exon 9 did not
lead to alternative use of exon 8 (Gilbert et al. 1993).
The level of ectopic KGFR expression differed between
cell lines, being highest in patient 1, with the Alu inser-
tion, intermediate in patient 3, with Pfeiffer syndrome
and the -2ArG mutation, and lowest in patient 4, with
Pfeiffer syndrome and the -2ArT mutation. To assess
the likely consequences that ectopic KGFR expression
has for limb development, we examined expression of
both the Kgfr and Bek isoforms in the embryonic mouse
limb bud. At E13, Kgfr was expressed only at low levels
in the interdigital or peridigital mesenchyme, whereas
Bek was expressed at much higher levels (fig. 8). Al-
though expression of Fgfr2 isoforms in the early limb
bud has not been examined in detail elsewhere, these
findings conform with the general conclusions of pre-
vious studies (Orr-Urtreger et al. 1993; Finch et al.
1995). Therefore, ectopic expression of Kgfr in the mes-
enchyme should extend the ligand sensitivity of the mes-
enchymal cells, to include FGF7 and FGF10 (Ornitz et
al. 1996; Xu et al. 1998). Previous studies confirm that
FGF10 is present at significant levels in the limb-bud
mesenchyme, whereas FGF7 expression occurs later,
once myogenesis and chondrogenesis are established
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Figure 8 E13 mouse embryonic limb buds hybridized with probes specific for Kgfr (A and C) and Bek (B and D). In situ hybridization
was performed on whole specimens (A and B), which were then sectioned (C andD). Both probes show hybridization to interdigitalmesenchyme,
but the level of Bek transcripts is much higher than that of Kgfr; Bek expression is also clearly detectable both around the digital cartilages
(arrow) and at the growing digital tips (B and D). In the surface ectoderm, Kgfr expression is stronger than Bek expression (C and D). Scale
bars represent 500 mm (in the case of A and B) and 20 mm (in the case of C and D).
(Mason et al. 1994; Finch et al. 1995; Ohuchi et al.
1997; reviewed by Martin 1998). By analogy with the
effects of increased FGF-induced signaling in the cranial
sutures (Iseki et al. 1997), this could favor skeletogenesis
in the limb-bud mesenchyme, both around the digital
cartilages and in the interdigital tissue, leading to
syndactyly.
If we assume that the magnitude of ectopic expression
observed in fibroblast lines from the patients reflects the
in vivo situation, then signal activation would be greater
for the patient with the Alu insertion than for the pa-
tients with Pfeiffer syndrome and would account for the
greater severity of limb abnormalities in patients with
Pfeiffer syndrome who have mutations of the exon 9
splice site compared with those who have other FGFR2
mutations. It is of interest that fibroblasts from patient
3 (with Pfeiffer syndrome) with the -2ArG mutation
showed higher ectopic KGFR expression than was seen
in those from the patient with the -2ArT mutation. The
patient with the Apert-like phenotype described by Pas-
sos-Bueno et al. (1997) had the -2ArG mutation, and
we speculate that chance effects (perhaps of genetic
background) led to abnormally high ectopic KGFR
expression in this individual, exceeding the threshold
required for syndactyly. Variability in ectopic KGFR
expression might account for the diversity of limb phe-
notypes (ranging from normal to Apert-like) in cranio-
synostosis families such as that described by Escobar and
Bixler (1977), although the mutation in that family has
not been reported.
Conclusions
Our observation of a correlation between ectopic
KGFR expression in fibroblasts and severity of syndac-
tyly provides, to our knowledge, the first genetic evi-
dence that the syndactyly of Apert syndrome is a KGFR-
mediated effect, as speculated in the original report of
FGFR2 mutations in Apert syndrome (Wilkie et al.
1995). Our model assumes that the effects observed in
fibroblasts reflect those in the early embryo. A report of
ectopic KGFR expression in fibroblasts from a patient
with syndromic acanthosis nigricans but not syndactyly
suggests that additional factors may be important
(Hughes et al. 1998). It should be noted that lower levels
of additional splice variants (6-7-10-11 and 6-7-11)were
observed. The 6-7-11 product has been described in
FGFR2, by Katoh et al. (1992), and may represent a
physiological splice variant (Johnston et al. 1995),
whereas the 6-7-10-11 product is out of frame and prob-
ably pathological. It is unclear to what extent these ad-
ditional splice variants may contribute to the phenotype.
Unfortunately, we were unable to study cell lines from
patient 2, in whom the Alu insertion occurred within
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exon 9 itself. We propose that this mutation would also
cause exon skipping, as has been described in the case
of BRCA2 (Miki et al. 1996). Clearly, we cannot for-
mally exclude other possibilities, such as expression of
the entire expanded exon or the activation of a cryptic
splice site within the Alu sequence (Makalowski et al.
1994). Nevertheless, the phenotypic similarity resulting
from the two Alu insertions argues that they act by a
shared pathological mechanism.
Our model proposes, by extension from these obser-
vations, that the syndactyly associated with canonical
Apert mutations (Ser252Trp and Pro253Arg) is also
KGFR mediated. By analogy with the in vitro effect that
the canonical Apert mutations have on the BEK isoform
(Anderson et al. 1998a), we anticipate that the canon-
ical mutations will cause reduced dissociation of
ligand(s)—most likely FGF7 or FGF10—from the KGFR
isoform. This would lead to enhanced KGFR-mediated
signaling, as postulated for the Alu insertion mutations.
Given the greater severity of syndactyly associated with
the Pro253Arg mutation (Slaney et al. 1996), this mu-
tation is expected to exhibit enhanced ligand affinity,
compared with Ser252Trp. Our hypothesis that the syn-
dactyly of Apert syndrome is KGFR mediated can be
further tested both by studies of in vitro binding of FGF
to mutant KGFR molecules and by analysis in animal
models.
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